House Bill Would Expand Rx Market, But Negatives Draw PhRMA Protest
This article was originally published in The Pink Sheet Daily
Executive Summary
Government negotiation of drug prices for the public plan option and Medicaid-level rebates for dual eligibles (individuals qualifying for Medicare and Medicaid) in Part D would be particularly hard for the industry to swallow.